
|Videos|July 2, 2013
Episode 17 - Conclusion: Treatment Advancements and Final Remarks
Advertisement
Episodes in this series

During this segment, Patricia K. Coyle, MD, Leslie Fish, PharmD, and Gary M. Owens, MD, explain how research has expanded in the neurology field and discuss the therapeutic pipeline for multiple sclerosis (MS) with Dr Fred Lublin.
Dr Coyle discusses the potential of newly developing agents and explains that clinical trials are now testing the efficacy of these products, which is vital when considering data for future clinical guidelines.
However, Dr Owens suggests that expensive costs of treatment and the lack of clinical recommendations or guidelines can cause confusion to clinicians and challenge the future of MS.
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
3
Real-World Brexu-cel Results in MCL Mirror Trials; Cost, QOL Data Lag
4
Four Ways to Boost Awareness, Access for COVID-19 PEP
5

















